| 2.97 -0.09 (-2.94%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.67 | 1-year : | 4.29 |
| Resists | First : | 3.14 | Second : | 3.67 |
| Pivot price | 2.9 |
|||
| Supports | First : | 2.64 | Second : | 2.32 |
| MAs | MA(5) : | 3.05 |
MA(20) : | 2.87 |
| MA(100) : | 2.52 |
MA(250) : | 2.25 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 79.1 |
D(3) : | 87.2 |
| RSI | RSI(14): 54.1 |
|||
| 52-week | High : | 3.45 | Low : | 1.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ERAS ] has closed below upper band by 37.3%. Bollinger Bands are 34.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.12 - 3.14 | 3.14 - 3.15 |
| Low: | 2.9 - 2.92 | 2.92 - 2.94 |
| Close: | 2.94 - 2.97 | 2.97 - 3 |
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Fri, 13 Sep 2024
Erasca (NASDAQ:ERAS) Shares Down 2% - MarketBeat
Tue, 10 Sep 2024
Erasca Insiders Enjoying US$2.5m Appreciation On US$3.97m Investment - Simply Wall St
Tue, 03 Sep 2024
Erasca, Inc. (NASDAQ:ERAS) Short Interest Update - MarketBeat
Tue, 13 Aug 2024
Erasca stock target raised on SEACRAFT-2 study optimism - Investing.com
Fri, 02 Aug 2024
Painful week for retail investors invested in Erasca, Inc. (NASDAQ:ERAS) after 6.1% drop, institutions also suffered losses - Simply Wall St
Thu, 23 May 2024
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 283 (M) |
| Shares Float | 204 (M) |
| Held by Insiders | 12.3 (%) |
| Held by Institutions | 76.8 (%) |
| Shares Short | 24,810 (K) |
| Shares Short P.Month | 22,260 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.64 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.2 % |
| Return on Equity (ttm) | -39 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -111 (M) |
| Levered Free Cash Flow | -87 (M) |
| PE Ratio | -3.2 |
| PEG Ratio | 0.8 |
| Price to Book value | 1.8 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|